- Home
- EDRY vs SLGL Comparison
EDRY vs SLGL Comparison
Compare EDRY & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | SLGL |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | Greece | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 117.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EDRY | SLGL |
|---|---|---|
| Price | $13.20 | $39.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 3.3K | ★ 15.3K |
| Earning Date | 11-13-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,384,447.00 | $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | $21.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $7.60 | $4.02 |
| 52 Week High | $16.14 | $52.26 |
Technical Indicators
Market Signals| Indicator | EDRY | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 54.64 |
| Support Level | $12.94 | $38.30 |
| Resistance Level | $13.75 | $44.04 |
| Average True Range (ATR) | 0.31 | 3.60 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 55.91 | 60.95 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.